WallStSmart

DaVita HealthCare Partners Inc (DVA)vsCharming Medical Limited Class A Ordinary Shares (MCTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 219178% more annual revenue ($13.64B vs $6.22M). MCTA leads profitability with a 19.3% profit margin vs 5.5%. DVA trades at a lower P/E of 16.1x. DVA earns a higher WallStSmart Score of 66/100 (B-).

DVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 8.7Quality: 4.3
Piotroski: 3/9Altman Z: 1.22

MCTA

Hold

37

out of 100

Grade: F

Growth: 7.3Profit: 8.0Value: 3.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$163.40

Current Price

$155.11

$8.29 discount

UndervaluedFair: $163.40Overvalued
MCTASignificantly Overvalued (-795.0%)

Margin of Safety

-795.0%

Fair Value

$3.28

Current Price

$29.36

$26.07 premium

UndervaluedFair: $3.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA3 strengths · Avg: 8.7/10
Return on EquityProfitability
64.8%10/10

Every $100 of equity generates 65 in profit

PEG RatioValuation
0.568/10

Growing faster than its price suggests

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

MCTA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
81.0%10/10

Earnings expanding 81.0% YoY

Operating MarginProfitability
28.9%8/10

Strong operational efficiency at 28.9%

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

MCTA4 concerns · Avg: 2.5/10
Market CapQuality
$504.26M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

P/E RatioValuation
419.4x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-3.3%2/10

Revenue declined 3.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.

Bull Case : MCTA

The strongest argument for MCTA centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 28.9%.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : MCTA

The primary concerns for MCTA are Market Cap, Return on Equity, P/E Ratio. A P/E of 419.4x leaves little room for execution misses.

Key Dynamics to Monitor

DVA profiles as a value stock while MCTA is a declining play — different risk/reward profiles.

DVA is growing revenue faster at 9.9% — sustainability is the question.

DVA generates stronger free cash flow (395M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (66/100 vs 37/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Charming Medical Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Charming Medical Limited, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. The company is headquartered in Causeway Bay, Hong Kong.

Want to dig deeper into these stocks?